SCHEMBL3842151

SCHEMBL3842151

CCC(CC)c1ccccc1CN

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 3/20 0.41
DPP4 P27487 2/20 0.39
TSHR P16473 1/20 0.38
TAAR1 Q96RJ0 1/20 0.34
CYSLTR2 Q9NS75 1/20 0.34
CYSLTR1 Q9Y271 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
OPRL1 P41146 1/20 0.34
NISCH Q9Y2I1 1/20 0.32
LOXL2 Q9Y4K0 2/20 0.32
NCF1 P14598 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
CSNK2A2 P19784 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22193240 0.84 CYSLTR2 (0.47) PNMTCYSLTR2CYSLTR1OPRM1OPRD1
SCHEMBL3840312 0.83 TAAR1 (0.50) TSHRTAAR1CYSLTR2CYSLTR1LOXL2
SCHEMBL6312079 0.83 DPP4 (0.43) PNMTDPP4TSHRTAAR1OPRM1
SCHEMBL9276125 0.82 GABRA1 (0.41) TSHRCYSLTR2CYSLTR1OPRM1OPRD1
SCHEMBL394464 0.81 TSHR (0.55) PNMTDPP4TSHRTAAR1NISCH
SCHEMBL9643567 0.81 PNMT (0.40) PNMTDPP4TSHRTAAR1OPRM1
SCHEMBL17180600 0.79 LMNA (0.47) PNMTDPP4TSHROPRM1OPRD1
SCHEMBL27860164 0.79 HTR2A (0.46) PNMTDPP4TSHRTAAR1OPRM1
SCHEMBL27406332 0.79 GABBR2 (0.36) TSHRTAAR1CYSLTR2CYSLTR1OPRM1
SCHEMBL12981697 0.78 TSHR (0.42) TSHRCYSLTR2CYSLTR1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108778997-B Method for the rapid calcination of zeolitic materials 巴斯夫欧洲公司 2023-01-17 CN disclosed
CN-109574822-B Series of tetraaryl spiro-compounds, preparation method and application thereof 天津师范大学 2021-12-21 CN disclosed
EP-3206991-A1 SOLIDOTHERMAL SYNTHESIS OF ZEOLITIC MATERIALS AND ZEOLITES OBTAINED THEREFROM BASF SE (DE) 2017-08-23 EP disclosed
EP-2130820-A1 Antipruritics SHIONOGI & CO., LTD. (JP) 2009-12-09 EP disclosed
EP-1477186-B1 ANTIPRURITICS SHIONOGI & CO (JP) 2009-11-11 EP disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-7420053-B2 2-imino-1,3-thiazine derivatives SHIONOGI & CO., LTD. (JP) 2008-09-02 US disclosed
EP-1375489-B1 MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE SHIONOGI & CO (JP) 2008-08-20 EP disclosed
EP-1219612-B1 2-IMINO-1,3-THIAZINE DERIVATIVES SHIONOGI & CO (JP) 2008-04-23 EP disclosed
US-20070088020-A1 2-imino-1,3-thiazine derivatives HANASAKI KOJI 2007-04-19 US disclosed
US-6916806-B2 Medicinal composition containing 1,3-thiazine derivative SHIONOGI & CO., LTD. (JP) 2005-07-12 US disclosed
US-20050124617-A1 2-Imino-1,3-thiazine derivatives HANASAKI KOJI (JP) 2005-06-09 US disclosed
US-20050101590-A1 Cannabinoid receptor agonists SHIONOGI & CO., LTD. (JP) 2005-05-12 US disclosed
EP-1477186-A1 ANTIPRURITICS SHIONOGI & CO., LTD. (JP) 2004-11-17 EP disclosed
US-6818640-B1 BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS SHIONOGI & CO., LTD. (JP) 2004-11-16 US disclosed
CN-1514831-A Medicinal composition containing 1,3-thiazine derivative ��Ұ����ҩ��ʽ���� 2004-07-21 CN disclosed
US-20040116326-A1 Medicinal composition containing 1,3-thiazine derivative SHIONOGI & CO., LTD. (JP) 2004-06-17 US disclosed
EP-1375489-A1 MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2004-01-02 EP disclosed
CN-1387519-A 2-imino-1, 3-thiazine derivatives SHIONOGI & CO (JP) 2002-12-25 CN disclosed
EP-1219612-A1 2-IMINO-1,3-THIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2002-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101590-A1 Cannabinoid receptor agonists CNR1, CNR2, OPRL1 PNMT 410/4885DPP4 2342/4885TSHR 773/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 PNMT 236/4885DPP4 1551/4885TSHR 1644/4885
US-20050124617-A1 2-Imino-1,3-thiazine derivatives CNR2, CNR1, HTR2C PNMT 389/4885DPP4 2280/4885TSHR 278/4885
US-20070088020-A1 2-imino-1,3-thiazine derivatives CNR2, CNR1, HTR2C PNMT 389/4885DPP4 2280/4885TSHR 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.